Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

109.62USD
7 Dec 2016
Change (% chg)

$-2.44 (-2.18%)
Prev Close
$112.06
Open
$111.89
Day's High
$111.89
Day's Low
$109.61
Volume
3,749,169
Avg. Vol
6,746,510
52-wk High
$126.07
52-wk Low
$94.28

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Friday, 19 Aug 2016 10:31am EDT 

Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16.  Full Article

Genmab to receive $15 mln in milestone payments from Janssen
Wednesday, 17 Aug 2016 03:40pm EDT 

Genmab A/S : Genmab announces submission of Supplemental Biologics License Application to FDA for daratumumab in relapsed multiple myeloma .Genmab to receive USD 15 million in milestone payments from Janssen.  Full Article

Janssen submits application to U.S. FDA to expand indication for daratumumab
Wednesday, 17 Aug 2016 03:25pm EDT 

Janssen Biotech Inc : Janssen submits application to u.s. Fda to expand indication for daratumumab (darzalex®) . Application seeks second indication for daratumumab in combination with standard of care regimens for patients with multiple myeloma .Has also submitted a request for priority review of sbla for daratumumab.  Full Article

Johnson & Johnson announces ruling related to Remicade
Wednesday, 17 Aug 2016 01:54pm EDT 

Johnson & Johnson : Johnson & Johnson announces ruling related to Remicade in the District of Massachusetts Federal Court hearing . Janssen is also continuing appeal process in proceedings related to 471 patent before U.S. Patent & Trademark office . Commercial launch of an infliximab biosimilar prior to outcome of appeals would be considered an at-risk launch .Reaffirms its sales guidance for operational sales growth for FY 2016 of 3 pct to 4 pct, notwithstanding possibility of a biosimilar launch on or after Oct. 3, 2016.  Full Article

Bristol-Myers Squibb collaborates with Johnson and Johnson for lung cancer research
Tuesday, 26 Jul 2016 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers squibb announces new research collaboration with janssen in immuno-oncology focused on lung cancer .Myers squibb co - phase 2 clinical trial will evaluate tolerability and clinical activity of combination of these agents in nsclc patients.  Full Article

Janssen says Health Canada approves Imbruvica for treatment of chronic lymphocytic leukemia
Wednesday, 20 Jul 2016 08:00am EDT 

Johnson & Johnson :Health Canada approves Imbruvica® (ibrutinib) for first-line treatment of chronic lymphocytic leukemia.  Full Article

Health Canada approves INVOKAMET for treatment of adults with type 2 diabetes
Wednesday, 20 Jul 2016 07:00am EDT 

Johnson & Johnson :Health Canada approves INVOKAMET for treatment of adults with type 2 diabetes.  Full Article

Johnson & Johnson posts Q2 earnings of $1.43/share
Tuesday, 19 Jul 2016 07:00am EDT 

Johnson & Johnson Reports 2016 Second : Johnson & Johnson reports 2016 second-quarter results . Q2 earnings per share $1.43 . Q2 sales $18.5 billion versus I/B/E/S view $17.97 billion . Q2 earnings per share view $1.68 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $6.63 to $6.73 . Q2 adjusted non-GAAP earnings per share $1.74 excluding items . Sees FY 2016 sales $71.5 billion to $72.2 billion . Worldwide medical devices sales of $6.4 billion for Q2 2016 represented an increase of 0.8% versus prior year . Ex-Items, on operational basis, Q2 worldwide sales increased 7.9%, domestic sales up 8.8 percent, intl sales up 6.9 percent . Fy2016 earnings per share view $6.61, revenue view $71.73 billion -- Thomson Reuters I/B/E/S . Q2 worldwide Velcade sales $342 million versus $304 million in Q1 . Q2 worldwide Zytiga sales $601 million versus $558 million in Q1 . Q2 worldwide Invokana/Invokamet sales $383 million versus. $325 million in Q1 . Worldwide pharmaceutical sales of $8.7 billion for q2 2016 represented an increase of 8.9% versus prior year . Operations in Venezuela negatively impacted worldwide consumer operational sales growth by 120 basis points in quarter . Qtrly operational sales results increased 5.3% and negative impact of currency was 1.4%. . Q2 worldwide Remicade sales $1,780 million versus $1,779 million in q1 . Q2 worldwide Olysio/Sovriad sales $43 million versus $32 million in q1.  Full Article

Ionis Pharmaceuticals licenses oral antisense drug to Janssen
Tuesday, 19 Jul 2016 07:00am EDT 

Ionis Pharmaceuticals Inc : Ionis Pharmaceuticals licenses first oral antisense drug acting locally in the GI tract to Janssen . Under terms of agreement, which covers three programs, Ionis is eligible to receive nearly $800 million in milestone payments . Will receive tiered royalties that on average are double-digits on sales from product that is successfully commercialized .Earned $10 million from Janssen Biotech Inc (Janssen) upon licensing IONIS-JBI1-2.5(Rx).  Full Article

Johnson & Johnson sets quarterly cash dividend of $0.80 per share
Monday, 18 Jul 2016 02:30pm EDT 

Johnson & Johnson :Sets quarterly cash dividend of $0.80 per share.  Full Article

Photo

J&J questions fairness of hip implant trial, $1 billion verdict

Johnson & Johnson will challenge the fairness of a trial that produced a verdict of $1 billion in damages against the company last week over allegations of design flaws in its Pinnacle hip implant.